Advances in antithrombotic treatment - antithrombotics with anti-Xa effect;Pokroky v antitrombotickej liečbe - Antitrombotiká s anti-Xa účinkom

Vnitrni Lekarstvi

Volumn 55, Issue 3, 2009, Pages 295-301

  Batorova A ^a  

^a Bratislava   (Slovakia)

Author keywords

FactorXa; New anticoagulants; Selective anti factorXa inhibitors

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ANTICOAGULANT AGENT; APIXABAN; BETRIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; DU 176B; DX 9056A; FONDAPARINUX; HEPARIN; IDRABIOTAPARINUX; IDRAPARINUX; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; OTAMIXABAN; PROTEIN C; RAZAXABAN; RIVAROXABAN; SSR 126517; UNCLASSIFIED DRUG; VITAMIN K GROUP; XARELTO; YM 150; MORPHOLINE DERIVATIVE; POLYSACCHARIDE; THIOPHENE DERIVATIVE;

ARTERY THROMBOSIS; HUMAN; RECURRENT DISEASE; REVIEW; RISK FACTOR; THROMBOEMBOLISM; THROMBOPHILIA; VEIN THROMBOSIS; DRUG ANTAGONISM;

ANTICOAGULANTS; FACTOR XA; HUMANS; MORPHOLINES; POLYSACCHARIDES; THIOPHENES; THROMBOEMBOLISM;

EID: 63849239365     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Rosendaal FE, Van Hylcama Vlieg A, Doggen JM. Venous thrombosis in elderly. J Thromb Haemost 2007; S (Suppl 1): 310-317.
2. Silverstein MD, Heit JA, Mohr DN et al. Trends in the incidence of deep venous thrombosis and pulmonary embolism: a 25 year population-based study. Arch Intern Med 1998; 158: 585-593.
3. HeitJA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 2005; 3: 1611-1617.
4. Stein PD, Hull RD, Kayali F et al. Venous thromboembolism according to age; impact of an aging population. Arch Intern Med 2004; 164: 2260-2263.
5. Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995; 75: 1-6.
6. Hoffman M, Monroe DM. III A cell- -based model of hemostasis. Thromb Haemost 2001; 85: 958-965.
7. WeitzJI, Bates SM. New anticoagulants. J Thromb Haemost 2005; 3: 1843-1853.
8. Ansell J. Faxtor Xa or thrombin: is factor Xa a better target? J Thromb Haemost 2007; 5: (Suppl 1): 60-64.
9. Weitz Jl. Factor Xa or thrombin: Is thrombin a better target? J Thromb Haemost 2007; 5 (Suppl 1): 65-67.
10. Abilgaard U. Highly purified antithrombin III with heparin cofactor activity prepared by disc electrophoresis. Scand J Clin Lab Invest 1968; 21: 89-91.
11. Rosenberg RD, Lam L. Corelations between structure and function of heparin. Proc Natl Acad Sci USA, 1979; 76: 1218-1222.
12. Lindahl U, Backtrom G, Hook M et al. Structure and antithrombin-binding site of heparin. Proc Natl Acad Sci USA 1979; 76: 3198-3202.
13. HirshJ. Low molecular weight heparins. 4th ed. Hamilton: BC Decker Inc 2007.
14. Johnson EA, Kirkwood TB, Stirling Y et al. Four heparin preparations: anti-Xa potentiating effect of heparin after subcutaneous injection. Thromb Haemost 1976; 35: 586-591.
15. Carter CJ, Kelton JG, Hirsh J et al. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239-1245.
16. WeitzJI. Low molecular-weight heparins. N EnglJ Med 1997; 337: 688-698.
17. Warkentin TE, Levine MN, HirshJ et al. Heparin-induced thrombocytopenia in patients treated with low-molecular weigh heparin or unfractionated heparin. N Eng J Med 1995; 3232: 1330-1335.
18. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia. Recognition, treatment and prevention. Chest 2004; 126 (Suppl 3): 311-337.
19. Hirsh J. Fondaparinux. Hamilton: BC Decker Inc 2007.
20. Kalicki RM, Aregger F, Alberio L et al. Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis. Thrombosis Haemost 2007; 98: 1200-1207.
21. Bijstervald NR, Moons AH, Boeckhold SM et al. Ability of recombinant factor Vlla to reverse the anticoagulant effect of the pentasacharide fondaparinux in healthy volunters. Circulation 2002; 106: 2550- 2554.
22. Turpie AGG, Eriksson Bl, Bauer KA et al. Fondaparinux. J Am Acad Ortop Surg 2004; 12: 371-375.
23. Savi P, Chong BH, Greinacher A et al. Effect of fondaparinux on platelet activation in the presence of heparin. Blood 2005; 105: 139-144.
24. Warkentin TE. HIT. Lessons learned. Pathophysiol Haemos Thromb 2006; 1-2: 50-57.
25. Harenberg J, Jorg l, Fenyvesi T. Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica 2004; 89: 1017-1018.
26. Efird L Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. Ann Pharmacother 2006; 40: 1383-1387.
27. Bátorová A, Skraková M, Labancová A et al. Manažment heparínom-indukovanej trombocytopénie. Interná medicińa 2006; 10:31.
28. Warkentin TE, Maurer BT, Aster RH et al. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007; 356: 2653-2654.
29. Weitz JI, HirshJ, Samama M. New anticoagulant drugs. Chest 2004; 126 (Suppl 3): 265-285.
30. Veyrat-Follet C, Vivier N, Trellu M et al. The pharmacokinetics of idraparinux, a long acting indirect factor xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials. J Thromb Haemost 2009; Epub ahead of print.
31. Eriksson Bl, Borris LC, Friedman RJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
32. Kakkar AK, Brenner B, Dahl OE et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-39.
33. Lassen MR, Ageno W, Borris LC et al. Rivaroxaban versus enoxaparin for thromboprophylaxis aftertotal knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
34. Abrams PJ, Emerson CR. Rivaroxaban, a novel direct oral anti Xa inhibitor. Pharmacotherapy 2009; 29: 167-181.
35. Carreiro J, Ansell J Apixaban, an oral direct FactorXa inhibitor: awaiting the verdict. Expert Opin Investig Drugs 2008; 17: 1937-1945.
36. Turpie AG, Bauer KA, Davidson BL et al. EXPERT Study Group. A randomized evaluation of betrixaban, an oral factor X inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost 2009; 101: 68-76.
37. Agnelli G, Haas S, Ginsberg JS at al. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost 2007; 5: 746-753.
38. Abraham E, Reinhart K, Opal S et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomised control trial. JAMA 2003; 290: 238- 247.
39. Golino P, Ragni M, Cirillo P et al. Antithrombotic effects of recombinant human, active site-blocked factor Vila in a rabbit model of recurrent and arterial thrombosis. Circulation Res 1998; 82: 39-46.
40. Jang Y, Guzman LA, Lincoff AM et al. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995; 92: 3041-3050.
41. Benedict CR, Ryan J, Wolitzky B et al. Active-site blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. J Clin Invest 1991; 88: 1760-1765.
42. Fuererstein GZ, Toomey JR, Valocik R et al. An inhibitory anti-factor IX antibody effectively reduces thrombus formation in a rat model of venous thrombosis. Thromb Haemost 1999; 92: 1443-1450.
43. White B, Livingstone W, Murphy C et al. An open label study of the adjuvant hemostatic support with protein C replacement in purpura fulminans-associated menongococcaemia. Blood 2000; 96: 3719-3724.
44. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant activated protein C for severe sepsis. N J Engl Med 2001; 344: 699-709.
45. Aoki Y, Ohishi R, Takei R et al. Effects of recombinant human soluble thrombomodulin (rhs-TM) on a rat model of disseminated intravascular coagulation with decreased levels of plasma antithrombin III. Thromb Haemost 1994; 71: 452-455.
46. Kaeron C, Comp P, Douketis J D et al. A dose-response study of recombinant human soluble thrombomodulin (ART-123) for prevention ofvenous thromboembolism sfter unilateral total hip replacement. J Thromb Haemost 2003; 1 (Suppl 1):OC330.
47. Baetz BE, Spinier SA. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 2008; 28: 1354-1373.